Business Context and Reporting Period
Company: AmerisourceBergen Corporation (Note: The input metadata lists "Cencora, Inc.", but the filing text identifies the registrant as AmerisourceBergen Corporation, the predecessor to Cencora).
Reporting Period: Fiscal year ended September 30, 2008.
Business Overview: One of the world's largest pharmaceutical services companies, operating primarily in the United States, Canada, and the United Kingdom. The company provides drug distribution and related services to healthcare providers (hospitals, pharmacies, physicians) and pharmaceutical manufacturers. Operations are organized into two reportable segments: Pharmaceutical Distribution and Other (which included Long-Term Care results prior to its July 2007 spin-off).
Key Financial Metrics
| Metric | Fiscal 2008 | Fiscal 2007 |
|---|---|---|
| Total Revenue | $70.19 billion | $65.67 billion |
| Gross Profit | $2.05 billion | $2.22 billion |
| Operating Income | $827.9 million | $788.7 million |
| Net Income | $250.6 million | $469.2 million |
| Diluted EPS (Total) | $1.54 | $2.50 |
| Cash and Cash Equivalents | $878.1 million | $640.2 million |
| Total Debt (Long-term + Current) | $1.19 billion | $1.23 billion |
| Stockholders' Equity | $2.71 billion | $3.10 billion |
Margins (as % of Total Revenue):
- Gross Profit: 2.92% (2008) vs. 3.38% (2007)
- Operating Income: 1.18% (2008) vs. 1.20% (2007)
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 7% to $70.19 billion, driven by a 7% increase in the Pharmaceutical Distribution segment. This growth was aided by the acquisition of Bellco Health (contributing 3%) and a shift in revenue recognition for bulk deliveries to operating revenue.
- Profitability Decline: Net income dropped significantly to $250.6 million from $469.2 million. This decline was primarily due to a $218.5 million loss from discontinued operations related to the divestiture of the PMSI workers' compensation business. This included a $225.8 million non-cash charge to write down PMSI goodwill and record the loss on sale.
- Operating Income: Operating income from continuing operations increased 5% to $827.9 million, despite a decrease in gross profit. The increase was driven by a 15% rise in Pharmaceutical Distribution operating income, offset by a $32.3 million decrease in gains from antitrust litigation settlements compared to the prior year.
- Divestitures: The company completed the sale of PMSI in October 2008. The Long-Term Care business was spun off in July 2007, and its results are no longer included in the current year's consolidated operations.
Guidance, Outlook, and Risks
Outlook: Management expects total revenue growth in fiscal 2009 to be between 1% and 3%. This projection reflects estimated market growth of 1%-2%, strong growth from large institutional customers, and the offsetting impact of losing approximately $3.0 billion in annual revenue from a large retail drug chain customer effective July 1, 2008.
Key Risks and Contingencies:
- Regulatory and Reimbursement: Significant exposure to changes in Medicare and Medicaid reimbursement rates (e.g., Deficit Reduction Act changes to Medicaid reimbursement formulas). Potential reductions in reimbursement for anemia drugs due to FDA safety warnings and CMS policy reviews.
- Customer Concentration: Medco Health Solutions accounted for 17% of total revenue in fiscal 2008. The top ten customers represented 42% of revenue.
- Legal Proceedings: Pending litigation includes the RxUSA matter (counterclaims for $61 million plus punitive damages), a New York Attorney General subpoena regarding alternate source market purchases, and ongoing resolution of the Bergen Brunswig executive compensation dispute.
- Market Volatility: The company faces risks from financial market volatility, including the bankruptcy of a lender (Lehman Commercial Paper) which reduced credit facility availability by $55 million, and the upcoming expiration of its receivables securitization facility in 2009.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the extent to which the $218.5 million loss from the PMSI divestiture obscures the underlying profitability of continuing operations.
- Customer Concentration: Assess the risk associated with Medco Health Solutions (17% of revenue) and the recent loss of a major retail chain customer ($3.0 billion in annual revenue).
- Regulatory Exposure: Monitor developments regarding Medicare Part B ASP calculations, Medicaid reimbursement rate changes, and FDA restrictions on anemia drugs, which could materially impact margins.
- Liquidity and Credit Facilities: Confirm the renewal status of the receivables securitization facility expiring in 2009 and the impact of credit market volatility on borrowing costs.
- Legal Reserves: Review the status of the RxUSA litigation and the New York Attorney General investigation for potential future liabilities.